322761-81-9

Basic information

• Product Name: ethyl 3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-1-thio-β-D-galactopyranoside 2,4,6-tribenzoate
• Synonyms: ethyl 3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-1-thio-β-D-galactopyranoside 2,4,6-tribenzoate
• CAS NO: 322761-81-9
• Molecular Weight: 780.936
• Mol File: 322761-81-9.mol

Chemical Properties

• CAS DataBase Reference: ethyl 3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-1-thio-β-D-galactopyranoside 2,4,6-tribenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-1-thio-β-D-galactopyranoside 2,4,6-tribenzoate(322761-81-9)
• EPA Substance Registry System: ethyl 3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-1-thio-β-D-galactopyranoside 2,4,6-tribenzoate(322761-81-9)

Safety Data

• Hazardous Substances Data: 322761-81-9(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 187404-16-6 benzyl (R)-3-cyclohexyl-2-trifluoromethanesulfonyloxy-propionate 
• 56245-60-4 ethyl 1-thio-β-D-galactopyranoside 
• 322761-80-8 ethyl 3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-1-thio-β-D-galactopyranoside 

Downstream Products

• 322761-84-2 1,5-anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-3-O-[2,4,6-tri-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-β-D-galactopyranosyl]-D-arabino-hexitol 
• 1361093-45-9 methyl 3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-2,4,6-tri-O-benzoyl-β-D-galactopyranosyl-(1->4)-[2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1->3)]-2-acetamido-6-O-benzyl-2-deoxy-β-D-glucopyranoside 
• 1361093-41-5 {(1R,2R,5R)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-5-methylcyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026074-12-3 {(1R,2R,3R)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-(2-methoxycarbonylethyl)cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026073-95-9 {(1R,2R,3R)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-cyclopropylcyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026074-07-6 {(1R,2R,3S)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-butylcyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026073-73-3 {(1R,2R,3S)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methylcyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026073-86-8 {(1R,2R,3S)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-ethylcyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026073-54-0 {(1R,3R,4R,5S)-4-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-1-methoxycarbonyl-5-methylcyclohex-3-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 1026074-36-1 {(1R,2R,3S,5R)-2-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3,5-dimethylcyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexylethyl]-β-D-galactopyranoside 
• 927881-64-9 C₇₈H₈₃N₃O₁₈ 
• 322761-78-4 O-3-O-[(1S)-1-cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-2,4,6-tris-O-(phenylmethyl)-β-D-galactopyranosyl-(1->3)-O-[6-deoxy-2,3,4-tris-O-(phenylmethyl)-α-L-galactopyranosyl-(1->4)]-1,5-anhydro-2-deoxy-D-arabino-hexitol 
• 322761-82-0 1,5-anhydro-2-deoxy-3-O-{2,4,6-tri-O-benzoyl-3-O-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-(phenylmethoxy)ethyl]-β-D-galactopyranosyl}-D-arabino-hexitol 
• 353233-31-5 C₇₂H₇₆O₁₆ 

Relevant articles and documents

GLYCOMIMETIC-PEPTIDOMIMETIC INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS

Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, glycomimetic-peptidomimetic compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.

HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS

Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.

PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY

Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular

GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINGS

Compounds and methods are provided for modulating in vivo and in vivo processes mediated by selectin biniding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g. inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids).

Substrate specificity of fucosyl transferase III: An efficient synthesis of sialyl Lewis(x) -, sialyl Lewis(a)- derivatives and mimetics thereof

Fucosyl transferase III (FucT III) has previously been characterized as the most general enzyme of the FucT family, as judged from its ability to catalyze the transfer of fucose to both Galβ(1-3)GlcNAc and Galβ(1-4)GlcNAc. In order to explore the synthetic potential of FucT III for the enzymatic synthesis of sialyl Lewis(x) and sialyl Lewis(a) derivatives, its substrate specificity has been probed using a number of natural substrate mimetics. A remarkable range of acceptor substrates was found when N-acetyl glucosamine was replaced by D-glucal, (R,R)-1,2-cyclohexanediol and (R,R)-butan-2,3-diol. Although the reaction rates were low compared to the reaction with the natural substrates, they proved to be sufficient for the synthesis of preparative amounts.

Potent E-selectin antagonists

In the search for drugs that could control excessive leukocyte extravasation, we now report on modifications of the already known potent E-selectin antagonist 3 containing a cyclohexyllactic acid residue and a glucal-derived building block. Thus, we describe the synthesis and biological evaluation of a series of derivatives 6 with modified glucal-derived moieties (CH2NR1R2 instead of CH2OH in 3) to explore a hypothetical potential complementary interaction with E-selectin. However, similar activity profiles of most derivatives 6 and compound 3 do not support such an interaction, but rather indicate topological-structure changes of 6 (and 3) in the orientation of the neighboring fucose and galactose due to intramolecular steric interactions. The most potent E-selectin antagonist 6v showed >50-fold improved E-selectin inhibition compared to the weak selectin ligand sialyl Lewis' (sLex, 1: IC50 = 1000-1500μM), but only a 2-fold improvement compared to 3. Compound 6x was tested in vivo in a murine model of acute inflammation and found to be as potent as 3 (ED50 = 15 mg/kg).